Le Lézard
Classified in: Health
Subject: VET

J P Systems, Inc. Celebrates C-CDA Interoperability Advancement


CLIFTON, Va., Nov. 13, 2017 /PRNewswire/ -- With extensive background in Clinical Systems Analysis, J P Systems, Inc.  subject matter experts helped achieve a key milestone this summer, contributing to improved Veteran's access to their own personal health records via "My HealtheVet".

My HealtheVet, (MHV), aims to provide veterans with a summary of their overall health and medical information that can be used for sharing with VA and non-VA clinicians.  In particular, My HealtheVet's VA Continuity of Care document (CCD) provides Veterans access to their health records and enables sharing of that information in a way that assures the records can be used by most non-VA clinicians the Veteran may choose to visit.

Marie Swall contributed significant efforts on the My HealteVet project, making sure that the CCD met requirements for national standards and for the needs of MHV for national deployment. Currently about 3 million Veterans now have access to their health record directly from My HealtheVet.  This new capability should have a significant impact on Veterans' health continuity of care.

Aside from this recent success, the President of J P Systems Jackie Mulrooney states, "Marie Swall reliably delivers extraordinary work and products to J P Systems Inc. and has been a great asset to the value of the solutions delivered by J P System's and our reputation with our government clients".

About J P Systems: Headquartered in Clifton, VA, J P Systems, Inc. (www.JPSys.com)  is one of Northern Virginia's leading Healthcare IT Solutions providers to the Federal Government.

J P Systems, Inc.
Phone: (703) 815 ? 0900
7419 Kincheloe Rd
Clifton, VA  20124
www.jpsys.com

SOURCE J P Systems Inc


These press releases may also interest you

at 16:35
Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial
Bristol Myers Squibb today announced the Phase 3 CheckMate -73L trial did not meet its primary endpoint of progression-free survival (PFS) in unresectable, locally advanced stage III non-small cell lung cancer (NSCLC). CheckMate -73L evaluated...

at 16:35
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Gossamer Bio, Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung...

at 16:35
Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock
Merrimack Pharmaceuticals, Inc. ("Merrimack" or the "Company") announced that the stockholders at a Special Meeting held today overwhelmingly approved adopting a Plan of Dissolution. Following that announcement, the Board of Directors declared a...

at 16:15
NOTICE TO THE MEDIA - Government of Canada to make an announcement supporting living environments that encourage physical activity in Quebec City
The Honourable Jean-Yves Duclos, MP for Québec and Minister of Public Services and Procurement, on behalf of the Honourable Mark Holland, Minister of Health, and  the Honourable Carla Qualtrough, Minister of Sport and Physical Activity, will announce...

at 16:15
CHEMISTREE ANNOUNCES COMPLETION OF DEBT RESTRUCTURING
Chemistree Technology Inc. and (the "Company" or "Chemistree"), announces that is has completed the previously announced restructuring transaction (the "Restructuring Transaction") to settle $6,668,000 in principal amount of outstanding 10% senior...

at 16:15
Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results
Edesa Biotech, Inc. , a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and six months ended March 31, 2024 and provided an...

More news about Health...


News published on and distributed by: